Faruqi and Faruqui, LLP Logo
Share this page

The Medicines Company (MDCO)

(NASDAQ: MDCO)

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In The Medicines Company To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in The Medicines Company (“Medicines” or the “Company”) (NASDAQ: MDCO) of the April 22, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Medicines and certain executives.

A complaint has been filed on behalf of all persons who purchased or otherwise acquired Medicines securities between February 20, 2013 and February 12, 2014, inclusive (the “Class Period”) in the District of New Jersey.

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s drug candidate, Cangrelor, did not show superiority when compared to clopidogrel, a competing drug previously approved by the FDA; and (ii) the Company’s CHAMPION clinical trials comparing Cangrelor’s efficacy with that of clopidorel were unethical and improperly administered. 

On February 12, 2014, the Company announced that the NASDAQ had halted the trading of its stock in connection with an FDA advisory panel.  Later that same day, the FDA advisory panel voted against approval of Cangrelor.

Following this news, the Company’s stock declined $3.82 per share, or over 11%, to close at $29.28 per share on February 13, 2014.

Take Action

If you invested in Medicines stock, bonds or options between February 20, 2013 and February 12, 2014 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Medicines’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 03/14/2014

Class Period:

  • 02/20/2013 - 02/12/2014

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.